<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713436</url>
  </required_header>
  <id_info>
    <org_study_id>2015-68</org_study_id>
    <nct_id>NCT04713436</nct_id>
  </id_info>
  <brief_title>The Effects of Antibiotic Combinations on Stem Cells</brief_title>
  <official_title>The Effects of Antibiotic Combinations on Mesenchymal Stem Cells Derived From Apical Papilla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eskisehir Osmangazi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eskisehir Osmangazi University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the indirect effects of antibiotic combinations.&#xD;
      SCAP viability, proliferation and apoptosis of the cells were evaluated. Osteocalcin (BGLAP),&#xD;
      dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels&#xD;
      were also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to evaluate the indirect effects of triple (TAP- ciprofloxacin,&#xD;
      metronidazole and minocycline), double (DAP- ciprofloxacin and metronidazole) and modified&#xD;
      triple antibiotic pastes (mTAP- ciprofloxacin, metronidazole and cefaclor) on mesenchmal stem&#xD;
      cells derived from apical papilla (SCAP). SCAP were isolated from the impacted third molar&#xD;
      teeth of the young adults. TAP, DAP and mTAP treatment (14-day medication and 28-day&#xD;
      medication) were applied on SCAP and viability, proliferation and apoptosis of the cells were&#xD;
      evaluated after four weeks. Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and&#xD;
      alkaline phosphatase (ALPP) gene expression levels were also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">February 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurment of Cell Viability and Apoptosis</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate cell viability and apoptosis MuseCell Analyzer Count and Viability kit (Merck Millipore, Taufkirchen, Germany) was used according to the manufacturer's protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurment of cell differantiation</measure>
    <time_frame>1 year</time_frame>
    <description>To determine gene expression levels, total RNA of SCAP was extracted using the Ambion PureLink RNA mini kit (Invitrogen, US) and the Roche cell RNA Kit (Penzberg, Germany) according to the manufacturer's instructions.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Stem Cells</condition>
  <condition>Anti-Bacterial Agents</condition>
  <arm_group>
    <arm_group_label>Triple antibiotic paste(TAP)</arm_group_label>
    <description>ciprofloxacin, metronidazole and minocycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doble antibiotic paste(DAP)</arm_group_label>
    <description>ciprofloxacin and metronidazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified triple antibiotic paste(mTAP)</arm_group_label>
    <description>ciprofloxacin, metronidazole and cefaclor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Differentiation Markers</intervention_name>
    <description>Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.</description>
    <arm_group_label>Doble antibiotic paste(DAP)</arm_group_label>
    <arm_group_label>Modified triple antibiotic paste(mTAP)</arm_group_label>
    <arm_group_label>Triple antibiotic paste(TAP)</arm_group_label>
    <other_name>Gene expression levels</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue samples were obtained from the apex of the extracted third molar teeth of young adult&#xD;
      patients aged between 16-22 (N=7).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tissue samples were obtained from the apex of the extracted third molar teeth of young&#xD;
        adult patients aged between 16-22 .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with open apex third molar teeth for extraction indication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with mature apex third molar teeth for extraction indication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seçil Çalışkan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eskişehir Osmangazi University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eskişehir Osmangazi University</name>
      <address>
        <city>Eskişehir</city>
        <zip>26040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eskisehir Osmangazi University</investigator_affiliation>
    <investigator_full_name>Seçil Çalışkan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

